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ABSTRACT
Proton pump inhibitors (PPIs) increase osteoporotic fracture risk presumably via hypochlorhydria and consequent reduced fractional
calcium absorption (FCA). Existing studies provide conflicting information regarding the direct effects of PPIs on FCA. We evaluated the
effect of PPI therapy on FCA. We recruited women at least 5 years past menopause who were not taking acid suppressants. Participants
underwentthree24-hourinpatientFCAstudiesusingthedualstableisotopemethod.TwoFCAstudieswereperformed1monthapartto
establish baseline calcium absorption. The third study occurred after taking omeprazole (40mg/day) for 30 days. Each participant
consumed the same foods during all FCA studies; study meals replicated subjects’ dietary habits based on 7-day diet diaries. Twenty-one
postmenopausal womenages58 7years (mean SD)completed all study visits. Seventeenwomen werewhite,and 2eachwereblack
andHispanic. FCA(mean SD)was20% 10%atvisit1,18% 10%atvisit2, and23% 10%following30 3days ofdailyomeprazole
(p¼.07, ANOVA). Multiple linear regression revealed that age, gastric pH, serum omeprazole levels, adherence to omeprazole, and 25-
hydroxyvitamin D levelswere unrelated to changes inFCA between study visits 2 and 3. The1,25-dihydroxyvitamin D3 level at visit 2was
the only variable (p¼.049) associated with the change in FCA between visits 2 and 3. PPI-associated hypochlorhydria does not decrease
FCA following 30 days of continuous use. Future studies should focus on identifying mechanisms by which PPIs increase the risk of
osteoporotic fracture.  2010 American Society for Bone and Mineral Research.
KEY WORDS: ACID SUPPRESSANT; BONE; CALCIUM ABSORPTION; FRACTURE; OSTEOPOROSIS
Introduction
P
roton pump inhibitors (PPIs) were identified recently as an
independentrisk factorforosteoporotic fracture.
(1–6)Millions
of American adults take PPIs to treat or prevent gastrointestinal
conditions.
(7) Indeed, PPIs rank second only to statins in drug
sales.
(8) Moreover, postmenopausal women account for over half
of long-term PPI users
(8) and represent the subset of individuals at
greatest risk for osteoporotic fracture. Therefore, this newly identi-
fied fracture risk factor has important public health ramifications.
Three large case-control studies
(1–3) and one retrospective
cohort study
(4) reported that PPI therapy increased the relative
risk of fracture by 1.15 [95% confidence interval (CI) 1.10–1.20]
(4)
to 1.92 (95% CI 1.16–3.18).
(3) Subsequently, three prospective
studies designed to identify risk factors for osteoporotic fracture
also found that PPI therapy was an independent risk factor for
fracture.
(5,6) Among 5339 women enrolled in the Study for
Osteoporotic Fractures, those reporting PPI use at the sixth visit
(n¼234) had a higher risk of nonvertebral fracture (relative
hazard¼1.34, 95% CI 1.10–1.64) during an average follow-up of
5 years.
(5) Among 5775 men enrolled in the Osteoporotic
Fractures in Men (MrOS) study, PPI use was associated with a
higher risk of fracture, but only in men not taking calcium
supplements (relative hazard¼1.49, 95% CI 1.04–2.14).
(5) In a
third prospective study, 5% of 1211 women were taking
omeprazole at study entry.
(6) Omeprazole therapy was an
independent risk factor for vertebral fracture (relative risk¼3.50,
95% CI 1.14–8.44) during 6 years of follow-up.
(6)
PPIshypotheticallyincreasetheriskofosteoporoticfractureby
causing hypochlorhydria, reduced intestinal calcium absorption,
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2786and subsequent negative calcium balance.
(5,7) Since calcium
solubility depends on the pH of the solution, calcium absorption
likewise may depend on gastric pH. This supposition was
supported by a study
(9) of 11 achlorhydric subjects who in the
fasting state demonstrated impaired absorption of a calcium
carbonate gelatin capsule but normal absorption of a calcium
citrate solution. However, absorption of calcium carbonate was
restored to normal when these subjects consumed calcium
carbonate capsules with breakfast.
(9) Typically, individuals ingest
calcium from dietary sources instead of supplements. Thus the
ability of achlorhydric patients to absorb calcium with a meal
would seem more applicable to the ability to absorb calcium
while taking PPIs.
Other studies cast significant doubt on the import of gastric
acid and calcium solubility on subsequent calcium absorption. In
onestudy,
(10)calciumcarbonatewasadministeredwithamealto
eight adults. Absorption of calcium carbonate was measured
twice by lavage, once when subjects’ gastric pH was maintained
at 7.4 using NaHCO3 infusion and again when gastric pH was
maintained at 3.0 using HCl infusion.
(10) Calcium absorption was
identical in both conditions despite a marked difference in
calcium carbonate solubility at differing pH.
(10) Subsequently,
another group performed a post hoc analysis of calcium
absorption data collected from 352 subjects across multiple
studies using calcium sources that varied in solubility by five
orders of magnitude.
(11) The relationship between calcium
solubility and absorption was weak; calcium absorption was
more strongly related to food components coingested with the
calcium salt.
(11)
Five studies
(12–16) (Table 1) have investigated the direct effect
of PPIs on intestinal calcium absorption with discordant results.
However, important limitations of these studies prevent
definitive conclusions regarding the effect of PPIs on calcium
absorption. First, none of the studies used dual isotopes to
measure calcium absorption, and three used serum calcium
levels, which correlate only weakly
(17) with absorption data
obtained using the ‘‘gold standard’’ dual-isotope method.
Second, the duration of PPI therapy was less than 12 days
in four studies. The Institute of Medicine recommends that
researchers wait 12 days for equilibrium to occur before
measuring changes in calcium homeostasis following an
intervention.
(18) Third, one study
(13) measured calcium absorp-
tion in the fasting state, which might not reflect calcium
absorption efficiency with a meal. Finally, one study
(12) did not
measure calcium absorption prior to the onset of PPI therapy.
It therefore remains uncertain whether PPI-associated hypo-
chlorhydria truly decreases calcium absorption.
We designed a prospective study using dual stable calcium
isotopes to evaluate changes in fractional calcium absorption
among postmenopausal women related to omeprazole therapy.
Table 1. Studies Assessing Changes in Calcium Absorption Related to PPI Therapy
Study Subjects Intervention
Calcium absorption
methodology Result
Serfaty-Lacrosniere,
1995
(12)
13 healthy adults,
medianage59years
Omeprazole 40 mg
daily for 7 days
Calcium consumed with
a meal, absorption
determined by
intestinal lavage
No difference in calcium
absorption between
treatment groups;
calcium absorption not
altered in all subjects
following gastric infusion
of 120 mL 0.1 M
hydrochloric acid
Graziani, 1995
(14) 8 healthy men, mean
age 38 years
Baseline and again after
omeprazole 20 mg
every 8 hours for 3 days
Postprandial increment
in serum calcium
Lack of increase in serum
calcium with omeprazole
therapy, suggesting
decreased calcium
absorption
Hardy, 1998
(16) 16 dialysis patients,
mean age 61 years
Baseline and again after
omeprazole 20 mg
daily for 2 months
Serum calcium measured
weekly at beginning
of dialysis
Lower serum calcium during
omeprazole therapy,
suggesting decreased
calcium absorption
Graziani, 2002
(15) 30 dialysis patients,
mean age 57 years
Baseline and again after
omeprazole 20 mg
every 8 hours for 3 days
Postprandial increment
in serum calcium
Lack of increase in serum
calcium with omeprazole
therapy, suggesting
decreased calcium
absorption
O’Connell, 2005
(13) Postmenopausal
women, mean age
76 years
Omeprazole 20 mg daily
for 7 days and placebo
daily for 7 days
Fasting serum
45Ca
isotope level 5 hours
after consuming
500 mg
45Ca carbonate
Calcium absorption
decreased from 9% to
4% following omeprazole
therapy (p<.05)
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Patient population
Women at least 5 years past the onset of menopause, defined
as the date of last menses, were eligible for participation. We
excluded women reporting an allergy to PPI, those taking
prescription medication for heartburn (PPI or H2-blocker
therapy), and those taking over-the-counter antacids within
the past 2 months. Women with intestinal conditions associated
with malabsorption or hypochlorhydria, stage 4 or 5 chronic
kidney disease, or nasal anatomy preventing nasogastric tube
placement also were excluded. We further barred women taking
medications known to alter calcium metabolism or interact with
omeprazole. The University of Wisconsin (UW) Human Subjects
Committee reviewed and approved the study protocol, and the
study was registered as a clinical trial (ClinicalTrials.gov identifier:
NCT00582972).
We recruited subjects through e-mail letters of invitation and
screened women who called our center via phone. Interested
and potentially eligible subjects underwent a screening visit to
confirm eligibility and provide written informed consent. We
recruited women of all races and ethnic groups. Race was
assessed and recorded at the screening visit because African
Americans absorb calcium more efficiently than white people.
(19)
Prior to the first calcium absorption study, subjects completed
7-day food diaries using a food scale. The study nutritionist (LAD)
used Food Processor software (ESHA Research, Salem, OR, USA)
to assess subjects’ energy, macronutrient, fiber, calcium, iron,
magnesium, sodium, vitamin D, oxalate, and caffeine intake. We
replicated each subject’s typical intake of all nutrients during
each of her 25-hour hospital stays; her breakfast, lunch, dinner,
and snacks were identical at each of the three study visits. Food
not consumed during each stay was bagged and weighed.
Subsequently, the study nutritionist analyzed subjects’ intake
of nutrients during each research admission. During the study,
subjects continued current nutritional supplement use to
ensure that changes in calcium absorption were unrelated to
changes in calcium intake. Throughout the study, investigators
tracked any changes in supplement use, including calcium
supplements.
Study interventions
We measured participants’ intestinal calcium absorption on
three separate occasions using the dual stable calcium isotope
protocol.
(20) Stable isotopes are calcium atoms of different
atomic weights with no radioactivity.
(21) The dual-isotope
method is considered the ‘‘gold standard’’ method by which
to measure calcium absorption
(21) owing to its accuracy, lack of
toxicity,
(21) and essentially identical biochemical behavior
(21) to
that of the dominant calcium atom,
40Ca. We administered one
isotope (
44Ca) orally to trace fractional calcium absorption (FCA)
and the other isotope (
42Ca) intravenously to trace renal and
intestinal calcium recycling. We used a formula
(20) incorporating
the isotope doses and their concentrations in participants’
24-hour urine collections to calculate FCA.
Trace Sciences International (Wilmington, DE, USA) provided
42Ca and
44Ca as calcium carbonate powder. The UW Waisman
Clinical Biomanufacturing Facility reconstituted isotopes into
calcium chloride solutions usingthe NIH protocol, including tests
for sterility and pyrogenicity.
(22) Once cleared for human use, the
isotope solutions were stored at the UW Pharmacy Research
Center until administration to subjects.
For all 24-hour inpatient FCA studies, subjects fasted
after midnight and arrived at the UW Center for Translational
and Clinical Research Core (CTRC) at 7:00 a.m. On arriving
on the ward, subjects emptied their bladder to provide a second
voidedurinesample formeasurementofC-telopeptide, amarker
of bone resorption. The 24-hour urine collection began
immediately after this void. Subsequently, an intravenous line
was placed and blood collected to measure parameters
associated with calcium homeostasis, including serum calcium,
creatinine, 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxy-
vitamin D3 [1,25(OH)2D3], and intact parathyroid hormone
(PTH).
During breakfast, subjects drank a small volume [50 7mL
(mean SD)] of Tropicana Pure Premium orange juice fortified
with calcium citrate malate and vitamin D (pH 4.3 0.1)
(23) and
mixed with approximately 8mg/16mL of
44Ca chloride solution.
Simultaneously, subjects received approximately 3mg/6mL of
42Ca intravenously followed by approximately 100mL of normal
saline. Nurses weighed isotope vials in duplicate before and
after use to record the administered doses of
42Ca and
44Ca.
Subsequently, nurses supervised complete inpatient 24-hour
urine collections and recorded subjects’ nutrient intake during
each stay. We calculated that 50mL of Tropicana orange juice at
a pH of 4.3
(23) contains 0.003mmol of H
þ ions. During breakfast,
humans secrete 37 4mmol of H
þ ions over 2hours.
(24)
Thus 50mL of orange juice does not significantly affect
gastric pH.
Weperformed two baseline absorption studies to evaluate the
monthly variability in FCA without intervention. The morning
prior to discharge during the first (n¼10) or second (n¼8)
study, we measured subjects’ fasting gastric pH via nasogastric
tube.
(25) We scheduled the third FCA study to occur on the
thirtieth day of omeprazole therapy. Subjects received a supply
of20-mgomeprazoletabletswithinstructionstotaketwotablets
at least ½ hour before breakfast every day. The third study
was identical to the first two, with the additional measurement
of morning serum omeprazole levels and pill counts to assess
adherence.
We chose a 30-day interval between subjects’ calcium
absorption study visits for two reasons. First, based on sequential
analysisofurineisotopelevels5daysfollowingdosinginanother
study,
(22) we estimated that the half-life of calcium isotopes was
approximately 21hours. Thus a 30-day interval between study
visits ensured that no residual isotope remained from the
prior study to spuriously elevate absorption measurements in
the next study. Second, the inhibitory effect of once-daily
omeprazole on gastric acid secretion plateaus after approxi-
mately 4 days (package insert). The Institute of Medicine
recommends that researchers wait 12 days for equilibrium to
occur before measuring changes in calcium homeostasis
following an intervention.
(18) We therefore decided to extend
the interval between study visits to 30 days in consideration of
these issues.
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The UW Hospital and Clinics Laboratory (Madison, WI, USA)
measured serum chemistries and intact PTH and 25(OH)D levels.
Personnel measured PTH using an electrochemiluminescence
immunoassay kit with reported intra- and interassay coefficients
of variation (CVs) of 4.3% and 3.3%, respectively. 25(OH)D levels
were measured using a semiautomated solid-phase-extraction
reverse-phase HPLC assay with intra- and interassay CVs of 4.2%
and 5.0%, respectively. Associated Regional University Pathol-
ogists (Salt Lake City, Utah, USA) measured 1,25(OH)2D3 using
a radioimmunoassay kit with intra- and interassay CVs of 7.7%
and 12.3%, respectively. The UW National Primate Center
Assay Services Laboratory (Madison, WI, USA) measured urine
C-telopeptide (CTX) using the b-crosslaps ELISA kit from
ImmunoDiagnostics Systems (Bolden, UK) with intra- and
interassay CVs of 1.0% and 10.9%, respectively.
Omeprazole levels were measured at the Primate Center
Laboratory following the methods of Zarghi and colleagues.
(26)
We thawed plasma samples and mixed 500mL of each sample
with50mLofcarbamazepine(internalstandard2mg/mL),500mL
of acetonitrile, and 100mL of saturated sodium chloride solution.
Samples were centrifuged for 15minutes at 8000rpm, and 40mL
of supernatant was injected onto an HPLC (Beckman Instru-
ments, System Gold, consisting of No. 126 solvent module, a No.
168 diode array detector, and a No. 508 autosampler) equipped
with a Chromolith Performance RP-18 endcapped 4.6 100mm
separation column (Merck, Darmstadt, Germany). Retention
times were (mean SE) 3.5 1.35minutes for omeprazole and
6.0 3.07minutes for carbamazepine as internal standards.
Standards (n¼7) were run at 3.0 to 250ng/40mL injection. All
samples were analyzed in duplicate in one single run; the
intraassay CV was 1.43%.
Wemeasuredthe calciumconcentrations and isotoperatios of
the urine samples at the Wisconsin State Lab of Hygiene using
high-resolution inductively coupled plasma mass spectrometry
(HR-ICP-MS; Finnigan Element 2, Thermo Instruments, Bremen,
Germany).
(27) Prior to analysis, we isolated calcium from urine by
oxalate precipitation.
(22) We diluted specimens to a total calcium
level of 6 1mg/L. Samples were introduced into the HR-ICP-MS
using a high-precision quartz cyclonic spray chamber and Teflon
medium-flow(400mL/min)nebulizer, anddata wereacquiredfor
three target isotopes (
42Ca,
43Ca, and
44Ca), doubly charged
strontium, and scandium (internal standard). Reference stan-
dards (High Purity Standards Calcium) were placed at frequent
intervals (every two samples) throughout the analytical
sequence to internally normalize the data and correct for
isotopic ratio drift, as well as reference ratios to a recognized
external NIST-traceable standard.
We obtained data in the medium-resolution mode (4000) of
the HR-ICP-MS to resolve all significant spectral interferences on
the target isotopes. Under typical operating conditions, the HR-
ICP-MS exhibited 0.2 10
6 counts/s of
43Ca (3 10
6 for
44Ca) at
the target Ca concentration. Typical precision for both reference
standards and urine samples was 0.2% to 0.4%. We analyzed
each urine sample on at least two occasions in separate batches
and used averages of data to calculate FCA. The Pearson
correlation coefficient for values obtained by duplicate analyses
of urine specimens was r¼0.98 (p<.0001) for
42Ca/
43Ca and
r¼0.97 (p<.0001) for
44Ca/
43Ca.
Study outcomes
The primary study outcome was the change in FCA following
1 month of omeprazole therapy. Secondary outcomes included
the change in bone resorption (CTX) and the monthly variability
in FCA at baseline, prior to omeprazole therapy.
Statistical analysis
Sample size calculations were based on data from a subset of
5452 women enrolled in the Study for Osteoporotic Fractures, in
whom an 8% lower FCA was associated with a 1.2-fold (95% CI
1.05–1.48) greater risk of hip fracture.
(28) In a previous study
at our center,
(22) the standard deviation for FCA between
postmenopausal women was 8% and within women was less
than 1%. Thus a sample size of 20 women allowed us to detect a
7% or greater difference in FCA after omeprazole therapy with
90% power and a two-sided type 1 error of 0.05. We planned
to recruit up to 25 women to allow for potential dropout during
the study.
For calculated values, we reported the mean SD unless
otherwise indicated. We used analysis of variance (ANOVA) with
the Bonferroni correction to compare within-subject changes for
FCA, bone resorption, laboratory characteristics, and dietary
habits. Multiple regression was used to evaluate relationships
between PPI-associated changes in FCA and subject variables,
including age, basal gastric pH, adherence to omeprazole, and
vitamin D metabolites [25(OH)D and 1,25(OH)2D3]. Variables
reflecting adherence included percent adherence, number of
omeprazole tablets taken, and serum omeprazole levels. We
completed all analyses using the R statistical analysis system
(Version 2.6.0).
(29)
Results
We recruited women by sending mass e-mail advertisements to
UW female faculty in January 2008 (Fig. 1). Eighty-three women
called our research center in response to the email, and 33 were
interestedandeligibleonthebasisofaphoneinterview.Twenty-
three women came to the CTRC and provided written informed
consent to enter the study. Two women could not complete the
7-day diet diary and withdrew from the study. Thus 21 women
completed all study visits.
Table 2 summarizes subjects’ characteristics (n¼21). Their
mean age was 58 7 years; 17 women were white, and 2 each
were black and Hispanic. Subjects’ mean 25(OH)D and PTH levels
at baseline were 28 13ng/mL and 49 24pg/mL, respectively.
Through the combination of dietary and supplemental intake,
subjects ingested 1400 650mg of calcium per day, approxi-
mately half (46%) consumed with breakfast. The calcium content
of the breakfast varied between subjects (700 600mg);
however, each woman’s calcium intake from diet and supple-
ments was identical at each of her three study visits. Twelve
subjects (57%) took supplements containing calcium prior to the
research study; these were continued during inpatient stays
(Table 2).
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woman carried a diagnosis of gastroesophageal reflux disease.
No participant reported antacid use within the past 2 months.
Threewomenhadsignificantgagreflexpreventingplacementof
thenasogastrictube.BaselinegastricpHwas3.4 1.8(range0to
6) among the remaining 18 women, similar to levels reported
among women in another study.
(30) Seven women had a
gastric pH between 0 and 3, and 11 had a gastric pH greater
than 3.
We measured subjects’ FCA at baseline, 39 17 days, and
64 2 days later, the third visit occurring 30 3 days after onset
of daily omeprazole therapy. The study group’s FCA (mean SD)
was 20% 10% at visit one, 18% 10% at visit two, and
23% 10% following omeprazole therapy (p¼.07, ANOVA;
Fig. 2). The mean change in FCA from visit 1 to visit 3 was
2% 7% and from visit 2 to visit 3 was 4% 8%.
We performed post hoc analyses to evaluate whether subsets
ofsubjectsexperiencedasignificantdeclineinFCAfromvisit2to
visit 3 following omeprazole therapy. FCA increased by 3% 6%
in 12 women taking calcium supplements and increased by
4% 10% in 9 women not taking calcium supplements (p¼.78
for the difference between groups). Similarly, FCA increased by
5% 8%among7womenwithagastricpH 3andincreasedby
1% 5% among 11 women with a gastric pH>3( p¼.24 for
the difference between groups). A scatter plot revealed no
correlation between baseline gastric pH and the change in FCA
between visit 2 and visit 3 (r¼ –0.17, p¼.52).
PTH and serum and urine calcium levels remained unchanged
following omeprazole (Table 2). Multiple regression models
revealed that age, serum omeprazole levels, percent adherence,
numberofomeprazole pillstaken, gastric pH,and25(OH)Dlevels
were unrelated to changes in FCA associated with omeprazole
therapy.The1,25(OH)2D3levelatvisit2wastheonlyvariablethat
was significantly associated with the change in FCA between
visits 2 and 3 (estimate –0.002, p¼.049).
Per protocol, participants ingested omeprazole 40mg daily for
30 3days.Basedonpillcounts,adherencewasexcellent(mean
adherence 98%,range 87%to100%).Amongparticipants, serum
Fig. 1. Study recruitment.
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Characteristics Screening Study 1 Study 2 Study 3
Anthropomorphic characteristics
Age, years 58 7 ———
Race 17 Caucasian — — —
2 Black
2 Hispanic
Body mass index, kg/m
2 —2 9  52 9  52 9  5
Laboratory characteristics
25(OH)D, ng/mL — 28 13 36 18 35 16
1,25(OH)2D3, pg/dL — 47 26 53 24 60  18
PTH, pg/mL — 49 24 50 22 49 20
Serum calcium, mg/dL — 9.1 0.4 9.2 0.3 9.2 0.4
Serum creatinine, mg/dL — 0.8 0.1 0.8 0.1 0.8 0.1
Urine calcium, mg/24 h — 153 67 152 64 146 46
Dietary habits
Kilocalories
a 2200 340 2100 310 2100 320 2100 300
Calcium, mg 1400 650 1400 650 1400 650 1400 650
Carbohydrates, g
b 270 60 250 50 250 50 250 50
Protein, g 88 21 84 20 83 20 83 20
Fat, g 87 22 85 22 85 23 85 23
Fiber, g 24 11 23 10 22 92 3  10
Vitamin D, IU
c 160 100 150 100 150 100 150 100
Sodium, mg
a 3400 890 3300 820 3300 810 3300 820
Magnesium, mg 360 110 360 120 360 110 360 110
Iron, mg 16 51 6   61 6  61 6  6
Caffeine, mg 170 150 160  110 160  110 160 110
Oxalate, servings 1.2 1.0 1.1 1.0 1.2 1 1.4 1
Note:Fractionalcalciumabsorptionstudies1,2,and3occurredatbaseline,39 17days,and64 2dayslater,respectively.Weusedanalysisofvariance
withaBonferronicorrectiontocomparewithin-subjectchangesinlaboratorycharacteristicsanddietaryhabitsduringstudyvisits.Fourdietaryparameters
were statistically different during inpatient visits compared with subjects’ usual dietary intake based on 7-day diet diaries secondary to incomplete meal
consumption.
ap<.0001.
bp¼.0015.
cp¼.005.
Fig. 2. We measured fractional calcium absorption in participants (n¼21) on three separate occasions. Each subject completed her third calcium
absorption study after taking omeprazole 40mg daily for 30 days. The study group’s mean FCA was 20% at visit one, 18% at visit two, and 23% following
omeprazole therapy (p¼.07, ANOVA). In this figure, we illustrate absorption using the means and 95% confidence intervals.
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levels reported in other studies.
(31) Two women took their last
omeprazole tablets the day prior to admission, but since
omeprazole suppresses gastric acid production for more than
24hours after dosing,
(32) we judged that measurements of
calcium absorption in these women would reflect the effects of
omeprazole on FCA. A post hoc analysis revealed no significant
PPI-induced change in FCA when excluding these 2 women from
the analysis.
No woman experienced severe side effects of omeprazole
warranting its discontinuation. Ten women identified mild
omeprazole side effects, including nausea (n¼2), diarrhea
(n¼2), constipation (n¼2), flatulence (n¼2), and headache
(n¼1). Onewomannotedasenseofscratching inher throatand
increased sputum production.
In vitro studies
(33) suggest that PPIs might decrease bone
resorption byinhibitingthe osteoclasticH
þ-ATPasepump, which
might improve bone health. However, two clinical studies
(34,35)
report divergent results on the effect of PPIs on bone resorption
in humans. Subjects’ CTX levels did not change significantly
during our study (p¼.80, ANOVA; Fig. 3). Subjects’ CTX values
were 1.9 1.0mg/mmol of creatinine at visit one, 1.8 1.0mg/
mmol of creatinine at visit two, and 1.9 0.9mg/mmol of
creatinine at visit three.
We used 7-day diet diaries to replicate subjects’ nutritional
habits during study visits. However, participants were not
required to eat 100% of meals during inpatient stays.
Subsequently, 4 of 12 dietary variables were statistically different
butnotclinicallydifferentduringinpatientstayswhencompared
withoutpatientfoodrecords(Table2).Indeed,thewithin-subject
SD for change in intake of kilocalories (111kcal), carbohydrates
(14g), vitamin D (12 IU), and sodium (122mg) represented small
percentage changes in typical intakes of these four nutrients
(ranging from 3.5% to 7%) that resemble daily variations in
dietary intake. We also calculated the potential renal acid load
(PRAL)
(36) of the breakfast meal (–3.4 7.9) and found no
relationship between PRAL and baseline FCA.
Discussion
Recent studies
(1–6) link PPI therapy to higher rates of
osteoporotic fracture, allegedly because PPI-induced hypochlor-
hydria decreases calcium solubility, leading to decreased
intestinal calcium absorption and negative calcium balance.
Althoughtheabsoluteincreaseinriskoffractureappearssmall,it
is important because millions of American adults take PPIs to
treat or prevent gastrointestinal conditions.
(7) Previous studies
have failed to establish unequivocally that PPIs increase fracture
risk by decreasing calcium absorption, but these studies have
potential limitations, as discussed earlier. We found that 30 days
of continuous PPI therapy did not decrease intestinal calcium
absorption in postmenopausal women. Additionally, subjects’
PTH, serum calcium, and urine calcium levels remained stable,
providing further evidence that PPIs do not alter calcium
absorption or calcium balance in the short term.
Our study had several strengths. We employed a ‘‘gold
standard’’ technique to measure FCA
(20) and conducted studies
on the inpatient ward, permitting complete 24-hour urine
collections. We replicated subjects’ nutritional habits during
studies in order to carefully assess the effect of PPI therapy on
FCA,independentofalterationsinnutritionalpractices,including
calcium intake. We performed two FCA studies at baseline in all
participants, thus controlling for age, dietary habits, and other
variables that can influence FCA independent of PPI therapy.
(37)
Adherence toomeprazole wasexcellent based onpill counts. We
used a prescription dose of omeprazole, permitting application
of study findings to other prescription-strength PPIs. The high
precision of our calcium absorption study method permitted the
ability to detect small changes in FCA. Among 21 subjects, the
Fig. 3. We assessed bone resorption by measuring participants’ (n¼21) fasting morning urine CTX levels. Subjects’ mean CTX values at visits 1, 2, and 3
were 1.9, 1.8, and 1.9mg/mmol of creatinine, respectively (p¼.80, ANOVA). In this figure we summarize CTX levels using the means and 95% confidence
intervals.
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1 and 2 was 8.2%. Thus we had 80% power to detect a 5.3% or
greater change in FCA following omeprazole and 75% power to
detect a 1% or greater change in FCA.
The greatest limitation of our study was its short-term nature.
The Institute of Medicine recommends that researchers wait
12 days for equilibrium to occur before measuring changes in
calcium homeostasis following an intervention.
(18) We extended
ourtreatmentintervalto30days,butthismightbeinsufficientto
detect true long-term changes in FCA from PPIs. Notably, many
patients take PPIs for years. A prospective intervention study of
longer duration should be performed to confirm the findings of
this study. Additionally, a study assessing changes in calcium
absorption following cessation of PPIs might be informative,
although rebound reflux symptoms might interfere with
successful ability to stop PPI therapy.
(38) Two participants took
their last dose of omeprazole the day prior to admission, but a
post hoc analysis indicated no differential change in FCA when
excluding these women. Additionally, omeprazole’s effect on
gastric acid production persists for more than 24hours after
dosing,
(32) with gradual return of gastric acidity 3 to 5 days after
cessation of therapy (package insert). We did not measure
gastric pH following omeprazole therapy and therefore cannot
determine whether women with greater changes in gastric pH
may have experienced a decrease in calcium absorption
following omeprazole therapy. Our participants were relatively
young and healthy; PPIs might decrease calcium absorption in
elderly adults or those with multiple comorbidities. Finally, PPI
therapy simply might mark people with impaired absorption of
nutrients owing to their underlying gastrointestinal illnesses; we
excluded such subjects from this study.
Subjects’ average 25(OH)D level indicated insufficiency during
the first calcium absorption study visit and sufficiency at
subsequent visits. However, wefound nostatistical differences in
subjects’ serum 25(OH)D levels throughout the study when
analyzing serum 25(OH)D as a continuous variable. Multivariate
analyses revealed that 25(OH)D was not a significant variable
affecting fractional calcium absorption. Finally, we would not
expect small changes in serum 25(OH)D levels to influence
fractional calcium absorption in a meaningful way based on our
previous publication,
(22) in which very large increments in serum
25(OH)D yielded only small increases in calcium absorption.
Indeed, using the dual stable calcium isotope technique, we
documentedthat calcium absorptionincreasedby only 3% 1%
(p¼.04) when subjects’ serum vitamin D levels increased from
22 4t o6 4  21ng/mL following prescription of high-dose
vitamin D.
It seems simplistic to believe that intestinal calcium absorp-
tion, 90% of which occurs in the small intestine, depends on
gastric acidity. While the stomach secretes 2500mL/day to
intestinal contents, these acidic secretions are neutralized by
approximately 3500mL of alkaline secretions, including saliva
( 1500mL), bile (500mL), and pancreatic juices (1500mL).
(39) As
a result, the pH of contents in the upper duodenum is typically
between 6.0 and 7.0.
(39) Thus, even without PPI therapy, chyme
entering the duodenum has a pH that is nearly neutral.
Higher dietary protein intake with a subsequently higher
dietary acid load seems to increase calcium absorption
compared with calcium absorption during a low-protein
diet.
(40,41) Thus, if our subjects consumed a high-protein diet
or had a high dietary acid load, we might be unable to detect a
PPI-mediated decrease in FCA. However, our subjects consumed
a low potential renal acid load, and their nutritional habits were
replicated during each study visit. Thus we feel that the acidity of
subjects’ meals had no significant impact on our study findings.
Three prospective studies, each designed to identify risk
factors for osteoporotic fracture, documented that PPI therapy is
an independent risk factor for osteoporotic fracture in older
adults.
(5,6) However, our study suggests that in postmenopausal
women this relationship is not due to a direct negative effect on
calcium absorption. We hypothesize that PPIs might adversely
affect skeletal health through a different, and possibly indirect,
mechanism that might be evident only following prolonged use.
PPIs might increase the risk of osteoporotic fracture by several
mechanisms. PPI use can cause vitamin B12 deficiency,
(42) which
might indirectly increase the risk of fracture by causing
peripheral neuropathy and increased falls or by causing high
homocysteine levels with adverse effects on cross-linking of
bone collagen.
(43–47) Additionally, PPI therapy might decrease
absorption of protein,
(48) with potential long-term adverse
effects on bone health. Bacterial overgrowth also can complicate
prolonged PPI therapy
(30,49) and might alter absorption of
nutrients, contributing to fracture risk.
In conclusion, 30 days of continuous PPI therapy did not alter
FCA in our cohort. Future studies should focus on identifying the
mechanisms by which PPIs increase the risk of osteoporotic
fracture to confirm a causal relationship. The underlying
gastrointestinal condition for which acid suppression is
prescribed might be the reason for a higher risk of osteoporotic
fracture rather than the treatment itself. Additionally, comorbid
diseases might explain the association between PPI therapy and
risk of fracture. In a survey of 168,727 adults,
(7) approximately 3%
received long-term acid-suppression therapy. Patients taking
acid suppressants had more medical illnesses and sought
medical care significantly more often than patients not taking
acid suppressants.
(7) Thus PPI therapy simply may mark
individuals who, owing to poor health, have a higher risk of
osteoporotic fracture.
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